Durvalumab (anti-PD-L1)

Durvalumab (anti-PD-L1) (MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity[1][2].

Product Specifications

CAS Number

[1428935-60-7]

Product Name Alternative

MEDI 4736 (anti-PD-L1)

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/durvalumab-anti-pd-l1.html

Purity

99.90

Solubility

10 mM in DMSO

Smiles

[Durvalumab(anti-PD-L1)]

Molecular Weight

(146.32 kDa)

References & Citations

[1]Faiena I, et al. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018 Jan 23;12:209-215.|[2]Stewart R, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015 Sep;3 (9) :1052-62.